Stay updated with breaking news from Bioaccord System. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Explore how we improved releasing N-glycan analysis in biotherapeutic development, which can help develop robust and unbiased glycan assays for...
Explore how we improved releasing N-glycan analysis in biotherapeutic development, which can help develop robust and unbiased glycan assays for...
To develop a robust peptide MAM assay, an LC system that delivers an unbiased and consistent protein digest separation is a necessity. This work...
May 11 2021 Waters Corporation (NYSE:WAT) has introduced a new peptide multi-attribute method (MAM) workflow for the Waters™ BioAccord™ LC-MS System, enabling drug development, manufacturing, and QC scientists to monitor efficacy and safety through the analysis of critical quality attributes (CQAs) of monoclonal antibodies (mAbs) and other protein-based drugs. “The BioAccord System moves attribute-based monitoring out of centralised MS labs and into the hands of more scientists in regulated and quality control laboratories who may not have extensive experience ...